Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
2026 · 2nd Quarter (Apr 1 - June 30)
BIOTECHNOLOGY INNOVATION ORGANIZATION
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- 84bf7c6c-e6ff-46c2-a624-5908d37a54ba
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.